Agilent (A) 10-Q 31 May 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Apr. 30, 2018	May 24, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	AGILENT TECHNOLOGIES INC.
Entity Central Index Key	1,090,872
Current Fiscal Year End Date	--10-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		319,952,126
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Apr. 30, 2018

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Net revenue:
Products	$ 918	$ 839	$ 1,848	$ 1,654
Services and other	288	263	569	515
Total net revenue	1,206	1,102	2,417	2,169
Costs and expenses:
Cost of products	402	364	785	711
Cost of services and other	160	146	315	292
Total costs	562	510	1,100	1,003
Research and development	91	84	184	163
Selling, general and administrative	338	307	679	596
Total costs and expenses	991	901	1,963	1,762
Income from operations	215	201	454	407
Interest income	10	5	19	9
Interest expense	(19)	(20)	(39)	(40)
Other income (expense), net	21	5	26	8
Income before taxes	227	191	460	384
Provision for income taxes	22	27	575	52
Net income (loss)	$ 205	$ 164	$ (115)	$ 332
Net income (loss) per share
Basic	$ 0.64	$ 0.51	$ (0.36)	$ 1.03
Diluted	$ 0.63	$ 0.50	$ (0.36)	$ 1.02
Weighted average shares used in computing net income (loss) per share:
Basic (in shares)	322	321	323	322
Diluted (in shares)	326	325	323	325
Cash dividends declared per common share	$ 0.149	$ 0.132	$ 0.298	$ 0.264

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Net income (loss)	$ 205	$ 164	$ (115)	$ 332
Other comprehensive income (loss):
Unrealized gain (loss) on derivative instruments, net of tax expense (benefit) of $1, $0 $(2)and $1	4	(1)	(3)	0
Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $2, $0, $2 and $(1)	3	(1)	3	(1)
Foreign currency translation, net of tax expense of $0, $1, $0 and $0	(53)	7	26	4
Net defined benefit pension cost and post retirement plan costs:
Change in actuarial net loss, net of tax expense of $3, $3, $5 and $11	7	9	13	26
Change in net prior service benefit, net of tax benefit of $0, $(1), $(1) and $(2)	(2)	(2)	(3)	(3)
Other comprehensive income (loss)	(41)	12	36	26
Total comprehensive income (loss)	$ 164	$ 176	$ (79)	$ 358

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Other comprehensive income (loss), tax, parenthetical disclosures
Unrealized gain (loss) on derivative instruments, tax	$ 1	$ 0	$ (2)	$ 1
Amounts reclassified into earnings related to derivative instruments, tax	2	0	2	(1)
Foreign currency translation, tax	0	1	0	0
Net defined benefit pension cost and post retirement plan costs, tax
Change in actuarial net loss, tax	3	3	5	11
Change in net prior service benefit, tax	$ 0	$ (1)	$ (1)	$ (2)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) - USD ($) $ in Millions	Apr. 30, 2018	Oct. 31, 2017
Current assets:
Cash and cash equivalents	$ 3,011	$ 2,678
Accounts receivable, net	754	724
Inventory	594	575
Other current assets	166	192
Total current assets	4,525	4,169
Property, plant and equipment, net	798	757
Goodwill	2,618	2,607
Other intangible assets, net	314	361
Long-term investments	139	138
Other assets	390	394
Total assets	8,784	8,426
Current liabilities:
Accounts payable	271	305
Employee compensation and benefits	271	276
Deferred revenue	333	291
Short-term debt	315	210
Other accrued liabilities	175	181
Total current liabilities	1,365	1,263
Long-term debt	1,800	1,801
Retirement and post-retirement benefits	226	234
Other long-term liabilities	776	293
Total liabilities	4,167	3,591
Commitments and Contingencies (Note 11)
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding	0	0
Common stock; $0.01 par value; 2 billion shares authorized; 322 million shares at April 30, 2018 and 322 million shares at October 31, 2017, issued	3	3
Additional paid-in-capital	5,332	5,300
Accumulated deficit	(412)	(126)
Accumulated other comprehensive loss	(310)	(346)
Total stockholder's equity	4,613	4,831
Non-controlling interest	4	4
Total equity	4,617	4,835
Total liabilities and equity	$ 8,784	$ 8,426

CONDENSED CONSOLIDATED BALANCE6

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (Parenthetical) - $ / shares	Apr. 30, 2018	Oct. 31, 2017
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	125,000,000	125,000,000
Preferred stock, issued and outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	2,000,000,000	2,000,000,000
Common stock, issued and outstanding (in shares)	322,000,000	322,000,000

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017
Cash flows from operating activities
Net income (loss)	$ (115)	$ 332
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	101	109
Share-based compensation	43	35
Deferred taxes	(13)	20
Excess and obsolete inventory related charges	17	15
Other non-cash expense, net	2	2
Changes in assets and liabilities:
Accounts receivable	(21)	(48)
Inventory	(34)	(29)
Accounts payable	(14)	6
Employee compensation and benefits	(7)	7
Change in assets and liabilities due to Tax Act	533	0
Other assets and liabilities	26	(76)
Net cash provided by operating activities	518	373
Net Cash Provided by (Used in) Investing Activities [Abstract]
Investments in property, plant and equipment	(108)	(75)
Payment to acquire cost method investment	(1)	0
Payments in exchange for convertible note	(2)	0
Change in restricted cash and cash equivalents, net	1	0
Proceeds from divestitures	0	1
Acquisitions of businesses and intangible assets, net of cash acquired	(7)	(70)
Net cash used in investing activities	(117)	(144)
Cash flows from financing activities:
Issuance of common stock under employee stock plans	36	26
Payment of taxes related to net share settlement of equity awards	(29)	(13)
Payment of dividends	(96)	(85)
Proceeds from revolving credit facility	356	228
Repayment of debt and revolving credit facility	(251)	(87)
Treasury stock repurchases	(93)	(194)
Net cash used in financing activities	(77)	(125)
Effect of exchange rate movements	9	(4)
Net increase in cash and cash equivalents	333	100
Cash and cash equivalents at beginning of period	2,678	2,289
Cash and cash equivalents at end of period	3,011	2,389
Supplemental cash flow information:
Income tax paid, net	48	41
Interest payments	43	40
Non-cash changes in investments in property, plant and equipment increase (decrease)	$ (21)	$ 8

OVERVIEW, BASIS OF PRESENTATION

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Notes)	6 Months Ended
	Apr. 30, 2018
Accounting Policies [Abstract]
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters. Basis of Presentation . We have prepared the accompanying financial data for the three and six months ended April 30, 2018 and 2017 pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2017 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2017 . In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of April 30, 2018 and October 31, 2017 , condensed consolidated statement of comprehensive income (loss) for the three and six months ended April 30, 2018 and 2017 , condensed consolidated statement of operations for the three and six months ended April 30, 2018 and 2017 , and condensed consolidated statement of cash flows for the six months ended April 30, 2018 and 2017 . Revision of Services and Other, Product Net Revenue and related Cost of Sales. In 2018, we identified a stream of service revenues that had been presented as product revenue in the prior year. We have now revised prior year's presentation to show the revenue within services and other to conform with the current presentation in fiscal 2018. The cost of sales associated with these newly identified service revenues has also been revised to align with the new presentation. For the three and six months ended April 30, 2017 service and other revenue increased $3 million and $6 million , respectively, and service and other cost of sales increased $2 million and $4 million , respectively, with corresponding reductions in product revenue and cost of sales. These corrections to the classifications are not considered to be material to current or prior periods and had no impact to our results of operations previously reported in our condensed consolidated statement of operations. Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, share-based compensation, retirement and post-retirement benefit plan assumptions, goodwill and purchased intangible assets and accounting for income taxes. Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). The company evaluates its investments in privately held companies on an ongoing basis. We have determined that as of April 30, 2018 there were no VIE’s required to be consolidated in the company’s consolidated financial statements because we do not have a controlling financial interest in any of the VIE’s that we have invested in nor are we the primary beneficiary. We account for these investments under either the equity or cost method, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. As of April 30, 2018 , the carrying value of our cost method investment in Lasergen, Inc. ("Lasergen"), a VIE, was $80 million with a maximum exposure of $80 million . The investments are included on the long-term investments line of the condensed consolidated balance sheet. Agilent’s initial ownership stake in Lasergen was 48 percent . During the three months ended April 30, 2018 , we exercised our option and signed the merger agreement to acquire all of the remaining shares of Lasergen, Inc. that we did not already own for an additional cash consideration of $105 million . The acquisition of Lasergen was completed on May 7, 2018. Acquisition. On March 7, 2018 we signed an agreement to acquire Advanced Analytical Technologies, Inc ("AATI") in a merger transaction for $250 million in cash, subject to certain purchase price adjustments. AATI, headquartered in Ankeny, Iowa, develops, manufactures and markets capillary electrophoresis based solutions for automated nucleic acid analysis. The financial results of AATI will be included within Agilent's from the date of the close. On May 31, 2018, we completed the acquisition of Advanced Analytical Technologies, Inc ("AATI"). Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments is determined using quoted market prices for those securities when available. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy is lower than the carrying value by approximately $4 million as of April 30, 2018 and exceeds the carrying value by approximately $58 million as of October 31, 2017 . The change in the fair value over carrying value in the six months ended April 30, 2018 is primarily due to fluctuations in market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 8, "Fair Value Measurements" for additional information on the fair value of financial instruments.

NEW ACCOUNTING PRONOUNCEMENTS (

NEW ACCOUNTING PRONOUNCEMENTS (Notes)	6 Months Ended
	Apr. 30, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
NEW ACCOUNTING PRONOUNCEMENTS	2. NEW ACCOUNTING PRONOUNCEMENTS There were no changes to the new accounting pronouncements not yet adopted as described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2017 except for the following: In May 2014, the Financial Accounting Standards Board ("FASB") issued new revenue recognition guidance, Accounting Standard Codification Topic 606, Revenue from contract with customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. The objective of the new revenue standard is to significantly enhance comparability and clarify principles of revenue recognition practices across entities, industries, jurisdictions and capital markets. The guidance is effective for us at the beginning in November 1, 2018. We expect to adopt this standard on November 1, 2018 through application of the modified retrospective method reflecting the cumulative effect of initially applying the new guidance to revenue recognition in the first quarter of fiscal 2019. Under the new guidance, there are specific criteria to determine if a performance obligation should be recognized over time or at a point in time. We expect that in some cases the revenue recognition timing under the new guidance will change from current practice. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements and disclosures. In February 2018, the FASB issued amendments to reporting comprehensive income to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act that was enacted in December 2017 that reduced the U.S. federal corporate income tax rate and made other changes to U.S. federal tax laws. The amendments in this update also require certain disclosures about stranded tax effects. The amendments are effective for us beginning November 1, 2019, and for interim periods within that fiscal year and should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. We expect to adopt this guidance on November 1, 2018. We are currently evaluating the impact the adoption of this guidance will have on our consolidated financial statements and disclosures. In February 2018, FASB issued technical corrections and improvements to amendments published in January 2016 to address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The provisions under these corrections and improvements are effective for us beginning November 1, 2018, and for interim periods within that year. Early adoption is not permitted. We currently do not expect this guidance to have a material impact on our consolidated financial statements and disclosures. In March 2018, FASB issued amendments to SEC Staff Accounting Bulletin (“SAB”) No. 118. These amendments modified certain SEC material in Topic 740 for the income tax accounting implications of the recently issued Tax Act and generally serves to codify the SEC’s guidance released in SAB No. 118. These amendments are effective for us beginning November 1, 2018, and interim periods with that year. We are currently evaluating the impact the adoption of this guidance will have on our consolidated financial statements and disclosures. Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

SHARE-BASED COMPENSATION (Notes

SHARE-BASED COMPENSATION (Notes)	6 Months Ended
	Apr. 30, 2018
Share-based Compensation [Abstract]
SHARE-BASED COMPENSATION	3. SHARE-BASED COMPENSATION Agilent accounts for share-based awards in accordance with the provisions of the authoritative accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our employee stock purchase plan (“ESPP”) and performance share awards granted to selected members of our senior management under the long-term performance plan (“LTPP”) based on estimated fair values. Participants in the LTPP are entitled to receive unrestricted shares of the company's stock after the end of a three-year period, if specified performance targets are met. Certain LTPP awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the Total Stockholders’ Return (“TSR”) set at the beginning of the performance period. Effective November 1, 2015, the Compensation Committee of the Board of Directors approved another type of performance stock award, for the company's executive officers and other key employees. Participants in this program are also entitled to receive unrestricted shares of the company's stock after the end of a three-year period, if specified performance targets over the three-year period are met. The performance target for grants made in 2016 were based on Operating Margin (“OM”) and the performance grants made in 2017 and 2018 were based on Earnings Per Share ("EPS"). The performance targets for the LTPP-EPS grants for year 2 and year 3 of the performance period will be set in the first quarter of year 2 and year 3, respectively. All LTPP awards granted after November 1, 2015, are subject to a one-year post-vest holding period. The final LTPP award may vary from zero to 200 percent of the target award. The maximum award value for awards granted in 2016 and 2017 cannot exceed 300 percent of the grant date target value. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant. The impact on our results for share-based compensation was as follows: Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 (in millions) Cost of products and services $ 3 $ 3 $ 10 $ 9 Research and development 1 1 4 3 Selling, general and administrative 8 11 29 24 Total share-based compensation expense $ 12 $ 15 $ 43 $ 36 At April 30, 2018 and October 31, 2017 , there was no share-based compensation capitalized within inventory. The following assumptions were used to estimate the fair value of awards granted. Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 LTPP: Volatility of Agilent shares 21% 23% 21% 23% Volatility of selected peer-company shares 14%-66% 15%-63% 14%-66% 15%-63% Price-wise correlation with selected peers 32% 36% 32% 36% Post-vest holding restriction discount for all executive awards 4.8% 5.3% 4.8% 5.3% Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulations model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock. For the volatility of our 2017 and 2018 LTPP (TSR) grants, we used our own historical stock price volatility. The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the price at purchase and uses the purchase date to establish the fair market value. The estimated fair value of restricted stock units, LTPP (OM) and LTPP (EPS) awards is determined based on the market price of Agilent’s common stock on the date of grant adjusted for expected dividend yield. The compensation cost for LTPP (OM) and LTPP (EPS) reflects the cost of awards that are probable to vest at the end of the performance period. All awards granted in 2016 and thereafter to our senior management employees have a one-year post-vest holding restriction. The estimated discount associated with post-vest holding restrictions is calculated using the Finnerty model (see table above). The model calculates the potential lost value if the employee were able to sell the shares during the lack of marketability period, instead of being required to hold the shares. The model used the same historical stock price volatility and dividend yield assumption used for the Monte Carlo simulations model and an expected dividend yield to compute the discount.

INCOME TAXES (Notes)

INCOME TAXES (Notes)	6 Months Ended
	Apr. 30, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	4. INCOME TAXES For the three and six months ended April 30, 2018 , the company's income tax expense was $22 million with an effective tax rate of 9.7 percent and $575 million with an effective tax rate of 125.0 percent , respectively. For the six months ended April 30, 2018, our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete charge of $533 million related to the enactment of the U.S. Tax Cuts and Jobs Act (the “Tax Act”) as discussed below. The income tax provision for the three and six months ended April 30, 2018 also includes the excess tax benefits from stock based compensation of $7 million and $18 million , respectively. For the three and six months ended April 30, 2017 , the company's income tax expense was $27 million with an effective tax rate of 14.1 percent and $52 million with an effective tax rate of 13.5 percent , respectively. The income tax provision for the three and six months ended April 30, 2017 included net discrete tax benefits of $1 million and $3 million , respectively. The significant component of the net discrete tax benefit for the three months ended April 30, 2017 included $5 million of tax benefit related to return-to-provision adjustments in foreign jurisdictions. The significant component of the net discrete tax benefit for the six months ended April 30, 2017 included a $11 million tax expense related to an employee pension settlement gain and $7 million of tax benefit for the settlement of an audit in Italy, and $5 million tax benefit related to return-to-provision adjustments in foreign jurisdictions. 2017 U.S. Tax Reform - Tax Cuts and Jobs Act On December 22, 2017, the Tax Cuts and Jobs Act ("Tax Act") was enacted into law. The Tax Act enacted significant changes affecting our fiscal year 2018, including, but not limited to, (1) reducing the U.S. federal corporate tax rate and (2) imposing a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries that had not been previously taxed in the U.S. The Tax Act also establishes new tax provisions affecting our fiscal year 2019, including, but not limited to, (1) creating a new provision designed to tax global intangible low-tax income (“GILTI”); (2) generally eliminating U.S. federal taxes on dividends from foreign subsidiaries; (3) eliminating the corporate alternative minimum tax (“AMT”); (4) creating the base erosion anti-abuse tax (“BEAT”); (5) establishing a deduction for foreign derived intangible income ("FDII"); (6) repealing domestic production activity deduction; and (7) establishing new limitations on deductible interest expense and certain executive compensation. The Tax Act reduces the U.S. federal corporate tax rate from 35 percent to 21 percent effective January 1, 2018. Due to our fiscal year end, the lower corporate tax rate will be phased in, resulting in a U.S. statutory federal rate of 23 percent for our fiscal year ending October 31, 2018 and 21 percent for subsequent fiscal years. ASC 740, Income Taxes, requires companies to recognize the effect of the tax law changes in the period of enactment. However, the SEC staff issued Staff Accounting Bulletin 118 ("SAB 118") which allows companies to record provisional amounts during a measurement period not extending beyond one year from the Tax Act enactment date. During the three months ended January 31, 2018, the company recognized a provisional amount of $533 million which includes (1) an estimated provision of $480 million of U.S. transition tax and correlative items on deemed repatriated earnings of non-U.S. subsidiaries and (2) an estimated provision of $53 million associated with the impact of decreased U.S. corporate tax rate as described below. As of April 30, 2018 , the company has not completed the accounting for all the impacts of the Tax Act. We were able to reasonably estimate certain effects and, therefore, recorded provisional adjustments associated with the Tax Act in the three months ended January 31, 2018, and they remain unchanged as of April 30, 2018. Deemed Repatriation Transition Tax ("Transition Tax") : The Transition Tax is based on the company’s total unrepatriated post-1986 earnings and profits ("E&P") of its foreign subsidiaries and the amount of non-U.S. taxes paid (Tax Pools) on such earnings. Historically, the company permanently reinvested a significant portion of these post-1986 E&P outside the U.S. For the remaining portion, the company previously accrued deferred taxes. Since the Tax Act required all foreign earnings to be taxed currently, the company recorded a provisional income tax expense of $643 million for its one-time transition U.S. federal tax and a benefit of $163 million for the reversal of related deferred tax liabilities. The resulting $480 million net transition tax, reduced by existing tax credits, will be paid over 8 years in accordance with the election available under the Tax Act. These amounts represent the best estimate of all required calculations based on currently available information and do not include any potential state tax impacts. The one-time Transition Tax is based in part on cash and illiquid asset amounts present on various comparable measurement dates, some of which are as of our future fiscal year end. As a result, the company’s calculation of the Transition Tax will change as the measurement dates occur and as federal and state tax authorities provide further guidance. Reduction of U.S. Federal Corporate Tax Rate : The reduction of the corporate income tax rate requires companies to remeasure their deferred tax assets and liabilities as of the date of enactment. The provisional amount recorded in the six months ended April 30, 2018 for the remeasurement due to tax rate change is $53 million . We have not yet completed our accounting for the measurement of deferred taxes. To calculate the remeasurement of deferred taxes, we estimated when the existing deferred taxes will be settled or realized. These estimates may be affected by activities in the remaining quarters and other analysis related to the Tax Act, including, but not limited to, the impact of state conformity to the tax law change. GILTI: The Tax Act subjects a U.S. corporation to tax on its GILTI. The U.S. GAAP allows companies to make an accounting policy election to either (1) treat taxes due on future GILTI inclusions in the U.S. taxable income as a current-period expense when incurred (“period cost method”) or (2) factoring such amounts into a company’s measurement of its deferred taxes (“deferred method”). Our analysis of the new GILTI rules and how they may impact us is incomplete. Accordingly, we have not made a policy election regarding the treatment of GILTI tax. Indefinite Reinvestment Assertion: The company incurred U.S. tax on substantially all of the prior accumulated earnings of its foreign subsidiaries as part of the Transition Tax. This increased the company’s previously taxed earnings and will allow for the repatriation of the majority of its foreign earnings without any U.S. federal tax. However, any repatriation of its foreign earnings could still be subjected to withholding taxes, state taxes or other income taxes that might be incurred. The company’s analysis is incomplete at this time with respect to its investments intentions for its accumulated foreign earnings. During the period prescribed by SAB 118, the company will evaluate, among other factors, the need for cash within and outside the United States, legal entity capitalization requirements, cash controls imposed in foreign jurisdictions, withholding taxes and the availability to offset with foreign tax credits in determining its investment assertion on its accumulated foreign earnings. Our estimates as described above, may change as a result of future guidance and interpretation from the Internal Revenue Service, the SEC, the FASB and various other taxing jurisdictions. In particular, we anticipate the U.S. state jurisdictions will continue to determine and announce their conformity or decoupling from the Tax Act either in its entirety or with respect to specific provisions. All of these potential legislative and interpretive actions could result in adjustments to our provisional estimates when the accounting for the income tax effects of the Tax Act is completed. There were no substantial changes from our 2017 Annual Report on Form 10-K to the status of the open tax years in the first six months of fiscal year 2018. In the U.S., tax years remain open back to the year 2014 for federal income tax purposes and the year 2000 for significant states. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2001. With these jurisdictions and the U.S., it is reasonably possible there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits.

NET INCOME PER SHARE (Notes)

NET INCOME PER SHARE (Notes)	6 Months Ended
	Apr. 30, 2018
Earnings Per Share [Abstract]
NET INCOME PER SHARE	5. NET INCOME PER SHARE The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below: Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 (in millions) Numerator: Net income (loss) $ 205 $ 164 $ (115 ) $ 332 Denominator: Basic weighted-average shares 322 321 323 322 Potential common shares— stock options and other employee stock plans 4 4 — 3 Diluted weighted-average shares 326 325 323 325 The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards. We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value were greater than the average market price of our common stock because their effect would also be anti-dilutive. For the three months ended April 30, 2018 , 96,800 potential common shares were excluded from the calculation of diluted earnings per share. For the six months ended April 30, 2018 , the diluted net loss per share is the same as basic net loss per share as the effects of all 6.6 million potential common shares outstanding would be anti-dilutive. For the three and six months ended April 30, 2017 , 1,000 and 500 potential common shares were excluded from the calculation of diluted earnings per share.

INVENTORY (Notes)

INVENTORY (Notes)	6 Months Ended
	Apr. 30, 2018
Inventory, Net [Abstract]
INVENTORY	6. INVENTORY April 30, October 31, (in millions) Finished goods $ 367 $ 363 Purchased parts and fabricated assemblies 227 212 Inventory $ 594 $ 575

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS (Notes)	6 Months Ended
	Apr. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	7. GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the six months ended April 30, 2018 : Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2017 $ 818 $ 1,285 $ 504 $ 2,607 Foreign currency translation impact 1 5 — 6 Goodwill arising from acquisitions 5 — — 5 Goodwill as of April 30, 2018 $ 824 $ 1,290 $ 504 $ 2,618 The components of other intangible assets as of April 30, 2018 and October 31, 2017 are shown in the table below: Purchased Other Intangible Assets Gross Carrying Amount Accumulated Amortization Net Book Value (in millions) As of October 31, 2017 Purchased technology $ 855 $ 646 $ 209 Trademark/Tradename 149 73 76 Customer relationships 151 112 39 Third-party technology and licenses 27 14 13 Total amortizable intangible assets 1,182 845 337 In-Process R&D 24 — 24 Total $ 1,206 $ 845 $ 361 As of April 30, 2018 Purchased technology $ 858 $ 676 $ 182 Trademark/Tradename 149 80 69 Customer relationships 151 124 27 Third-party technology and licenses 28 17 11 Total amortizable intangible assets 1,186 897 289 In-Process R&D 25 — 25 Total $ 1,211 $ 897 $ 314 During the six months ended April 30, 2018 , we recorded additions to goodwill of $5 million and additions to other intangible assets of $2 million related to an acquisition. We also acquired approximately $1 million of third party technologies and licenses during the six months ended April 30, 2018. During the six months ended April 30, 2018 , other intangible assets, net increased $2 million due to the impact of foreign exchange translation. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. There were no indicators of impairments of indefinite-lived intangible assets or goodwill during the three and six months ended April 30, 2018 and 2017 , respectively. Amortization expense of intangible assets was $26 million and $52 million for the three and six months ended April 30, 2018 , respectively. Amortization expense of intangible assets was $32 million and $64 million for the three and six months ended April 30, 2017 , respectively. Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2018 and for each of the five succeeding fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) Remainder of 2018 $ 47 2019 $ 71 2020 $ 56 2021 $ 42 2022 $ 31 2023 $ 21 Thereafter $ 21

FAIR VALUE MEASUREMENTS (Notes)

FAIR VALUE MEASUREMENTS (Notes)	6 Months Ended
	Apr. 30, 2018
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	8. FAIR VALUE MEASUREMENTS The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability. Fair Value Hierarchy The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value: Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data. Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial assets and liabilities measured at fair value on a recurring basis as of April 30, 2018 were as follows: Fair Value Measurement at April 30, 2018 Using April 30, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 2,171 $ 2,171 $ — $ — Derivative instruments (foreign exchange contracts) 6 — 6 — Long-term Trading securities 30 30 — — Total assets measured at fair value $ 2,207 $ 2,201 $ 6 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 8 $ — $ 8 $ — Long-term Deferred compensation liability 30 — 30 — Total liabilities measured at fair value $ 38 $ — $ 38 $ — Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2017 were as follows: Fair Value Measurement at October 31, 2017 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,659 $ 1,659 $ — $ — Derivative instruments (foreign exchange contracts) 4 — 4 — Long-term Trading securities 32 32 — — Total assets measured at fair value $ 1,695 $ 1,691 $ 4 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 6 $ — $ 6 $ — Long-term Deferred compensation liability 32 — 32 — Total liabilities measured at fair value $ 38 $ — $ 38 $ — Our money market funds and trading securities investments are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on quoted market prices, the inputs used in the calculations are observable. Trading securities, which is comprised of mutual funds, bonds and other similar instruments, and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive loss within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income. Impairment of Investments. There were no impairments of investments for the three and six months ended April 30, 2018 and 2017 . Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis For the three and six months ended April 30, 2018 and 2017 , there were no impairments of long-lived assets held and used or long-lived assets held for sale.

DERIVATIVES (Notes)

DERIVATIVES (Notes)	6 Months Ended
	Apr. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES	9. DERIVATIVES We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts, purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates. Fair Value Hedges We are exposed to interest rate risk due to the mismatch between the interest expense we pay on our loans at fixed rates and the variable rates of interest we receive from cash, cash equivalents and other short-term investments. We have issued long-term debt in U.S. dollars at fixed interest rates based on the market conditions at the time of financing. The fair value of our fixed rate debt changes when the underlying market rates of interest change, and, in the past, we have used interest rate swaps to change our fixed interest rate payments to U.S. dollar LIBOR-based variable interest expense to match the floating interest income from our cash, cash equivalents and other short term investments. As of April 30, 2018 , all interest rate swap contracts had either been terminated or had expired. On August 9, 2011, we terminated five interest rate swap contracts related to our 2020 senior notes that represented the notional amount of $500 million . The remaining gain to be amortized at April 30, 2018 was $9 million . All deferred gains from terminated interest rate swaps are being amortized over the remaining life of the respective senior notes. Cash Flow Hedges We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. Changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in other income (expense) each period. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified to cost of sales in the condensed consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense) in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense) in the condensed consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in other income (expense) over the life of the option contract. For the three and six months ended April 30, 2018 and 2017 ineffectiveness and gains and losses recognized in other income (expense) due to de-designation of cash flow hedge contracts were not significant. In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 10, 2012. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at April 30, 2018 was $1 million . In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million and we recognized this as a deferred loss in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at April 30, 2018 was $8 million . Other Hedges Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative are recognized in other income (expense) in the condensed consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities. Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties. A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions. The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of April 30, 2018 , was $5 million . The credit-risk-related contingent features underlying these agreements had not been triggered as of April 30, 2018 . There were 110 foreign exchange forward contracts open as of April 30, 2018 and designated as cash flow hedges. There were 156 foreign exchange forward contracts open as of April 30, 2018 not designated as hedging instruments. The aggregated notional amounts by currency and designation as of April 30, 2018 were as follows: Derivatives Designated as Cash Flow Hedges Derivatives Not Designated as Hedging Instruments Forward Contracts USD Forward Contracts USD Currency Buy/(Sell) Buy/(Sell) (in millions) Euro $ (67 ) $ 77 British Pound (48 ) (3 ) Canadian Dollar (41 ) 3 Australian Dollar 5 15 Malaysian Ringgit — (1 ) Japanese Yen (64 ) 9 Danish Krone — 26 Korean Won (42 ) — Singapore Dollar 15 — Swiss Franc — 36 Chinese Yuan Renminbi (45 ) — Polish Zloty — (8 ) Swedish Krona — (10 ) Other — (7 ) Totals $ (287 ) $ 137 Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of April 30, 2018 and October 31, 2017 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location April 30, October 31, Balance Sheet Location April 30, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 3 $ 2 Other accrued liabilities $ 3 $ 2 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 3 $ 2 Other accrued liabilities $ 5 $ 4 Total derivatives $ 6 $ 4 $ 8 $ 6 The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows: Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 (in millions) Derivatives designated as hedging instruments: Cash Flow Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive income (loss) $ 5 $ (1 ) $ (5 ) $ 1 Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales $ (5 ) $ 1 $ (5 ) $ 2 Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense) $ (5 ) $ — $ 1 $ (3 ) At April 30, 2018 , the estimated amount of existing net gain that is expected to be reclassified from accumulated other comprehensive income (loss) to cost of sales within the next twelve months is $2 million .

RETIREMENT PLANS AND POST RETIR

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Notes)	6 Months Ended
	Apr. 30, 2018
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	10. RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Components of net periodic costs. For the three and six months ended April 30, 2018 and 2017 , our net pension and post retirement benefit costs were comprised of the following: Three Months Ended April 30, U.S. Non-U.S. U.S. Post Retirement Benefit Plans 2018 2017 2018 2017 2018 2017 (in millions) Service cost—benefits earned during the period $ — $ — $ 4 $ 4 $ — $ — Interest cost on benefit obligation 4 5 3 3 1 2 Expected return on plan assets (7 ) (6 ) (12 ) (10 ) (2 ) (2 ) Amortization: Actuarial losses — 1 8 9 2 2 Prior service credits — (1 ) — — (2 ) (2 ) Total net plan costs $ (3 ) $ (1 ) $ 3 $ 6 $ (1 ) $ — Settlements gains $ — $ — $ — $ — $ — $ — Six Months Ended April 30, U.S. Non-U.S. U.S. Post Retirement 2018 2017 2018 2017 2018 2017 (in millions) Service cost—benefits earned during the period $ — $ — $ 10 $ 8 $ — $ — Interest cost on benefit obligation 8 8 6 6 2 3 Expected return on plan assets (14 ) (12 ) (23 ) (20 ) (4 ) (4 ) Amortization: Actuarial losses — 2 15 18 4 5 Prior service credits — (1 ) — — (4 ) (4 ) Total net plan costs $ (6 ) $ (3 ) $ 8 $ 12 $ (2 ) $ — Settlements gains $ — $ — $ (5 ) $ (32 ) $ — $ — We made no contributions to our U.S. defined benefit plans during the three and six months ended April 30, 2018 . We contributed $5 million and $11 million to our non-U.S. defined benefit plans during the three and six months ended April 30, 2018 , respectively. We contributed $25 million to our U.S. defined benefit plans during the three and six months ended April 30, 2017 . We contributed $6 million and $9 million to our non-U.S. defined benefit plans during the three and six months ended April 30, 2017 , respectively. We do not expect to contribute to our U.S. defined benefit plans during the remainder of 2018 and we expect to contribute $12 million to our non-U.S. defined benefit plans during the remainder of 2018 . Japanese Welfare Pension Insurance Law . In Japan, Agilent has employees' pension fund plans, which are defined benefit pension plans established under the Japanese Welfare Pension Insurance Law (JWPIL). The plans are composed of (a) a substitutional portion based on the pay-related part of the old-age pension benefits prescribed by JWPIL (similar to social security benefits in the United States) and (b) a corporate portion based on a contributory defined benefit pension arrangement established at the discretion of the company. During the six months ended April 30, 2017 , Agilent received government approval and returned the substitutional portion of Japan's pension plan to the Japanese government, as allowed by the JWPIL. The initial transfer resulted in a net gain of $32 million which was recorded within cost of sales and operating expenses in the condensed consolidated statement of operations. The net gain consisted of two parts - a gain of $41 million , representing the difference between the fair values of the Accumulated Benefit Obligation (ABO) settled of $65 million and the assets transferred from the pension trust to the government of Japan of $24 million , offset by a settlement loss of $9 million related to the recognition of previously unrecognized actuarial losses included in accumulated other comprehensive income. In the first quarter of fiscal year 2018, after the Japanese government’s final review of our initial payment, we received a refund of $5.2 million which was recorded as a settlement gain.

WARRANTIES AND CONTINGENCIES (N

WARRANTIES AND CONTINGENCIES (Notes)	6 Months Ended
	Apr. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
WARRANTIES AND CONTINGENCIES	11. WARRANTIES AND CONTINGENCIES Warranties We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net product shipments. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our condensed consolidated balance sheet. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product. A summary of the standard warranty accrual activity is shown in the table below: Six Months Ended April 30, 2018 2017 (in millions) Beginning balance as of November 1, $ 34 $ 35 Accruals for warranties including change in estimate 25 24 Settlements made during the period (26 ) (25 ) Ending balance as of April 30, $ 33 $ 34 Accruals for warranties due within one year $ 33 $ 33 Accruals for warranties due after one year — 1 Ending balance as of April 30, $ 33 $ 34 Contingencies We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are probable and reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.

SHORT-TERM DEBT (Notes)

SHORT-TERM DEBT (Notes)	6 Months Ended
	Apr. 30, 2018
Short-term Debt [Abstract]
SHORT-TERM DEBT	12. SHORT-TERM DEBT Credit Facilities On September 15, 2014 , Agilent entered into a credit agreement with a group of financial institutions which provides for a $400 million five -year unsecured credit facility that will expire on September 15, 2019 . On June 9, 2015, the commitments under the existing credit facility were increased by $300 million and on July 14, 2017, the commitments under the existing credit facility were increased by an additional $300 million so that the aggregate commitments under the facility now total $1 billion . As of April 30, 2018 , the company had borrowings of $315 million outstanding under the credit facility. We were in compliance with the covenants for the credit facility during the three and six months ended April 30, 2018 . In May 2018, the outstanding balance under our existing credit facility was paid in full. 2017 Senior Notes In October 2007 , the company issued an aggregate principal amount of $600 million in senior notes ("2017 senior notes"). On October 20, 2014, we settled the redemption of $500 million of the $600 million outstanding aggregate principal amount of our 2017 senior notes. The remaining $100 million in senior notes matured on November 1, 2017 and were paid in full.

LONG-TERM DEBT (Notes)

LONG-TERM DEBT (Notes)	6 Months Ended
	Apr. 30, 2018
Debt Disclosure [Abstract]
LONG-TERM DEBT	13. LONG-TERM DEBT Senior Notes The following table summarizes the company’s long-term senior notes and the related interest rate swaps: April 30, 2018 October 31, 2017 Amortized Principal Swap Total Amortized Principal Swap Total (in millions) 2020 Senior Notes 499 9 508 499 11 510 2022 Senior Notes 399 — 399 398 — 398 2023 Senior Notes 596 — 596 596 — 596 2026 Senior Notes 297 — 297 297 — 297 Total $ 1,791 $ 9 $ 1,800 $ 1,790 $ 11 $ 1,801 All outstanding notes listed above are unsecured and rank equally in right of payment with all of Agilent’s other senior unsecured indebtedness. There have been no changes to the principal, maturity, interest rates and interest payment terms of the Agilent senior notes, detailed in the table above, in the six months ended April 30, 2018 as compared to the senior notes described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2017 . All interest rate swap contracts have been terminated and amounts to be amortized over the remaining life of the senior notes as of April 30, 2018 and October 31, 2017 are detailed above.

STOCKHOLDERS' EQUITY (Notes)

STOCKHOLDERS' EQUITY (Notes)	6 Months Ended
	Apr. 30, 2018
Stockholders' Equity Note [Abstract]
STOCKHOLDERS EQUITY	14. STOCKHOLDERS' EQUITY Stock Repurchase Program On May 28, 2015, we announced that our board of directors had approved a new share repurchase program (the "2015 repurchase program"). The 2015 repurchase program authorizes the purchase of up to $1.14 billion of our common stock at the company's discretion through and including November 1, 2018. The 2015 repurchase program does not require the company to acquire a specific number of shares and may be suspended or discontinued at any time. During the three and six months ended April 30, 2018 , we repurchased 674,000 shares for $46 million and 1.3 million shares for $93 million , respectively, under this authorization. During the three and six months ended April 30, 2018 , we retired approximately 711,000 treasury shares for $49 million and 1.3 million treasury shares for $93 million , respectively. During the three and six months ended April 30, 2017 , we repurchased and retired approximately 1.6 million shares for $83 million and 4.1 million shares for $194 million , respectively, under this authorization. As of April 30, 2018 , we had remaining authorization to repurchase up to $517 million of our common stock under this program. Cash Dividends on Shares of Common Stock During the three and six months ended April 30, 2018 , we paid cash dividends of $0.149 per common share or $48 million and $0.298 per common share or $96 million on the company's common stock, respectively. During the three and six months ended April 30, 2017 , we paid cash dividends of $0.132 per common share or $43 million and $0.264 per common share or $85 million on the company's common stock, respectively. On May 16, 2018 , our board of directors declared a quarterly dividend of $0.149 per share of common stock or approximately $48 million which will be paid on July 25, 2018 to all shareholders of record at close of business on July 3, 2018 . The timing and amounts of any future dividends are subject to determination and approval by our board of directors. Accumulated Other Comprehensive Income (Loss) Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Three Months Ended April 30, 2018 Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of January 31, 2018 $ (77 ) $ 139 $ (322 ) $ (9 ) $ (269 ) Other comprehensive income (loss) before reclassifications (53 ) — — 5 (48 ) Amounts reclassified out of accumulated other comprehensive income (loss) — (2 ) 10 5 13 Tax expense — — (3 ) (3 ) (6 ) Other comprehensive income (loss) (53 ) (2 ) 7 7 (41 ) As of April 30, 2018 $ (130 ) $ 137 $ (315 ) $ (2 ) $ (310 ) Six Months Ended April 30, 2018 As of October 31, 2017 $ (156 ) $ 140 $ (328 ) $ (2 ) $ (346 ) Other comprehensive income (loss) before reclassifications 26 — (1 ) (5 ) 20 Amounts reclassified out of accumulated other comprehensive income (loss) — (4 ) 19 5 20 Tax (expense) benefit — 1 (5 ) — (4 ) Other comprehensive income (loss) 26 (3 ) 13 — 36 As of April 30, 2018 $ (130 ) $ 137 $ (315 ) $ (2 ) $ (310 ) Reclassifications out of accumulated other comprehensive income (loss) for the three and six months ended April 30, 2018 and 2017 were as follows (in millions): Details about accumulated other comprehensive income (loss) components Amounts Reclassified from other comprehensive income (loss) Affected line item in statement of operations Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 Unrealized gain (loss) on derivatives $ (5 ) $ 1 $ (5 ) $ 2 Cost of products (5 ) 1 (5 ) 2 Total before income tax 2 — 2 (1 ) (Provision) benefit for income tax (3 ) 1 (3 ) 1 Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (10 ) (12 ) (19 ) (34 ) Prior service benefit 2 3 4 5 (8 ) (9 ) (15 ) (29 ) Total before income tax 3 2 4 8 Benefit for income tax (5 ) (7 ) (11 ) (21 ) Total net of income tax Total reclassifications for the period $ (8 ) $ (6 ) $ (14 ) $ (20 ) Amounts in parentheses indicate reductions to income and increases to other comprehensive income (loss). Reclassifications out of accumulated other comprehensive income (loss) of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost together with curtailments and settlements (see Note 10 "Retirement Plans and Post Retirement Pension Plans").

SEGMENT INFORMATION (Notes)

SEGMENT INFORMATION (Notes)	6 Months Ended
	Apr. 30, 2018
Segment Reporting [Abstract]
SEGMENT INFORMATION	15. SEGMENT INFORMATION Description of segments. We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Agilent has three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business each of which comprises a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments. A description of our three reportable segments is as follows: Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry (“MP-AES”) instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps and measurement technologies. Our diagnostics and genomics business is comprised of five areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as active pharmaceutical ingredients ("API") in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Next, our pathology solutions business is focused on product offerings to cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry (“IHC”), in situ hybridization (“ISH”), hematoxylin and eosin (“H&E”) staining and special staining. We also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Finally, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. The majority of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, software as a service, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements. A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, real estate, insurance services, information technology services, treasury, order administration, other corporate infrastructure expenses and costs of centralized research and development. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate amortization and impairment of acquisition-related intangible assets, pension curtailment or settlement gains, restructuring and transformational initiatives expenses, acquisition and integration costs, business exit and divestiture costs, special compliance costs, some nucleic acid solutions division ("NASD") site costs and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations, in-sourcing or outsourcing of activities. The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments. The profitability of each of the segments is measured after excluding restructuring and asset impairment charges, transformational initiatives, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below: Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 (in millions) Net Revenue: Life Sciences and Applied Markets $ 561 $ 523 $ 1,179 $ 1,063 Diagnostics and Genomics 219 201 404 365 Agilent CrossLab 426 378 834 741 Total net revenue $ 1,206 $ 1,102 $ 2,417 $ 2,169 Segment Income From Operations: Life Sciences and Applied Markets $ 119 $ 110 $ 278 $ 236 Diagnostics and Genomics 44 49 66 72 Agilent CrossLab 98 82 186 156 Total segment income from operations $ 261 $ 241 $ 530 $ 464 The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes: Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 (in millions) Total reportable segments’ income from operations $ 261 $ 241 $ 530 $ 464 Transformational initiatives (5 ) — (9 ) (2 ) Amortization of intangible assets related to business combinations (25 ) (31 ) (50 ) (62 ) Acquisition and integration costs (4 ) (7 ) (7 ) (21 ) Business exit and divestiture costs (8 ) — (8 ) — Pension settlement gain — — 5 32 NASD site costs (2 ) — (4 ) — Special compliance costs (1 ) — (2 ) — Other (1 ) (2 ) (1 ) (4 ) Interest income 10 5 19 9 Interest expense (19 ) (20 ) (39 ) (40 ) Other income (expense), net 21 5 26 8 Income before taxes, as reported $ 227 $ 191 $ 460 $ 384 The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets. April 30, October 31, (in millions) Segment Assets: Life Sciences and Applied Markets $ 1,758 $ 1,753 Diagnostics and Genomics 2,136 2,119 Agilent CrossLab 1,173 1,138 Total segment assets $ 5,067 $ 5,010

SUBSEQUENT EVENTS - (Notes)

SUBSEQUENT EVENTS - (Notes)	6 Months Ended
	Apr. 30, 2018
Subsequent Event [Line Items]
Subsequent Events	16. SUBSEQUENT EVENTS Credit Facility. In May 2018, the outstanding balance under our existing credit facility was paid in full. Declaration of Dividends. On May 16, 2018 , our board of directors declared a quarterly dividend of $0.149 per share of common stock or approximately $48 million which will be paid on July 25, 2018 to all shareholders of record at close of business on July 3, 2018 . Acquisitions. On May 7, 2018, we completed the acquisition of Lasergen, Inc. (Lasergen), an emerging biotechnology company focused on research and development of innovative technologies for DNA sequencing, for an additional cash consideration of $105 million . On May 14, 2018, we acquired 100 percent of the stock of Genohm SA (“Genohm”), an international lab informatics company, for approximately $40 million in cash. Genohm, headquartered in Switzerland, provides lab informatics services specific to compliance, traceability, and big lab data management. On May 31, 2018, we completed the acquisition of Advanced Analytical Technologies, Inc ("AATI") for approximately $250 million in cash. On May 23, 2018, we signed an agreement to acquire certain assets from Young In Scientific Co. Ltd., a leading distributor of analytical and scientific instruments in South Korea, for cash. The acquisition is subject to local laws and regulations and customary closing conditions. The financial results of the business related to the acquired assets will be included within our financial results from the date of the close, which is expected to be during the fourth quarter of 2018. On May 25, 2018, we signed an agreement to acquire substantially all of the assets and liabilities of Ultra Scientific Incorporated, a global manufacturer and supplier of analytical standards and certified reference materials, for cash. The acquisition is subject to local laws and regulations and customary closing conditions. The financial results of the business related to the acquired assets will be included within our financial results from the date of the close, which is expected to be during the third quarter of 2018. In total, the cash payment for both asset acquisitions will be approximately $60 million . Segment Reporting Changes . In May 2018, we announced we will re-organize our microfluidics business, which currently is included in our life science and applied markets segment, will be moved to our diagnostics and genomics operating segment. Following this re-organization, Agilent will continue to have three businesses - life sciences and applied markets, diagnostics and genomics and Agilent Crosslab- each of which will comprise a reportable segment. All historical segment numbers will be recast to conform to this new reporting structure in our financial statements, beginning with our Form 10-Q filing for the third quarter of 2018.

OVERVIEW, BASIS OF PRESENTATI24

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Apr. 30, 2018
Accounting Policies [Abstract]
Overview, Segment Structure and Basis of Presentation	Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters. Basis of Presentation . We have prepared the accompanying financial data for the three and six months ended April 30, 2018 and 2017 pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2017 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2017 . In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of April 30, 2018 and October 31, 2017 , condensed consolidated statement of comprehensive income (loss) for the three and six months ended April 30, 2018 and 2017 , condensed consolidated statement of operations for the three and six months ended April 30, 2018 and 2017 , and condensed consolidated statement of cash flows for the six months ended April 30, 2018 and 2017 . Revision of Services and Other, Product Net Revenue and related Cost of Sales. In 2018, we identified a stream of service revenues that had been presented as product revenue in the prior year. We have now revised prior year's presentation to show the revenue within services and other to conform with the current presentation in fiscal 2018. The cost of sales associated with these newly identified service revenues has also been revised to align with the new presentation. For the three and six months ended April 30, 2017 service and other revenue increased $3 million and $6 million , respectively, and service and other cost of sales increased $2 million and $4 million , respectively, with corresponding reductions in product revenue and cost of sales. These corrections to the classifications are not considered to be material to current or prior periods and had no impact to our results of operations previously reported in our condensed consolidated statement of operations.
Use of Estimates	Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, share-based compensation, retirement and post-retirement benefit plan assumptions, goodwill and purchased intangible assets and accounting for income taxes.
Variable Interest Entity Disclosure	Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). The company evaluates its investments in privately held companies on an ongoing basis. We have determined that as of April 30, 2018 there were no VIE’s required to be consolidated in the company’s consolidated financial statements because we do not have a controlling financial interest in any of the VIE’s that we have invested in nor are we the primary beneficiary. We account for these investments under either the equity or cost method, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. As of April 30, 2018 , the carrying value of our cost method investment in Lasergen, Inc. ("Lasergen"), a VIE, was $80 million with a maximum exposure of $80 million . The investments are included on the long-term investments line of the condensed consolidated balance sheet. Agilent’s initial ownership stake in Lasergen was 48 percent . During the three months ended April 30, 2018 , we exercised our option and signed the merger agreement to acquire all of the remaining shares of Lasergen, Inc. that we did not already own for an additional cash consideration of $105 million . The acquisition of Lasergen was completed on May 7, 2018.
Fair Value of Financial Instruments	Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments is determined using quoted market prices for those securities when available. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy is lower than the carrying value by approximately $4 million as of April 30, 2018 and exceeds the carrying value by approximately $58 million as of October 31, 2017 . The change in the fair value over carrying value in the six months ended April 30, 2018 is primarily due to fluctuations in market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 8, "Fair Value Measurements" for additional information on the fair value of financial instruments.

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	6 Months Ended
	Apr. 30, 2018
Share-based Compensation [Abstract]
Allocated share-based compensation expense disclosure	The impact on our results for share-based compensation was as follows: Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 (in millions) Cost of products and services $ 3 $ 3 $ 10 $ 9 Research and development 1 1 4 3 Selling, general and administrative 8 11 29 24 Total share-based compensation expense $ 12 $ 15 $ 43 $ 36
Assumptions used to estimate fair value for LTPP	The following assumptions were used to estimate the fair value of awards granted. Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 LTPP: Volatility of Agilent shares 21% 23% 21% 23% Volatility of selected peer-company shares 14%-66% 15%-63% 14%-66% 15%-63% Price-wise correlation with selected peers 32% 36% 32% 36% Post-vest holding restriction discount for all executive awards 4.8% 5.3% 4.8% 5.3%

NET INCOME PER SHARE (Tables)

NET INCOME PER SHARE (Tables)	6 Months Ended
	Apr. 30, 2018
Earnings Per Share [Abstract]
Reconciliation of the numerators and denominators of the basic and diluted net income per share	The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below: Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 (in millions) Numerator: Net income (loss) $ 205 $ 164 $ (115 ) $ 332 Denominator: Basic weighted-average shares 322 321 323 322 Potential common shares— stock options and other employee stock plans 4 4 — 3 Diluted weighted-average shares 326 325 323 325

INVENTORY (Tables)

INVENTORY (Tables)	6 Months Ended
	Apr. 30, 2018
Inventory, Net [Abstract]
INVENTORY	6. INVENTORY April 30, October 31, (in millions) Finished goods $ 367 $ 363 Purchased parts and fabricated assemblies 227 212 Inventory $ 594 $ 575

GOODWILL AND OTHER INTANGIBLE28

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	6 Months Ended
	Apr. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill balances and movements for each reportable segments during the period	The following table presents goodwill balances and the movements for each of our reportable segments during the six months ended April 30, 2018 : Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2017 $ 818 $ 1,285 $ 504 $ 2,607 Foreign currency translation impact 1 5 — 6 Goodwill arising from acquisitions 5 — — 5 Goodwill as of April 30, 2018 $ 824 $ 1,290 $ 504 $ 2,618
Components of other intangibles during the period	The components of other intangible assets as of April 30, 2018 and October 31, 2017 are shown in the table below: Purchased Other Intangible Assets Gross Carrying Amount Accumulated Amortization Net Book Value (in millions) As of October 31, 2017 Purchased technology $ 855 $ 646 $ 209 Trademark/Tradename 149 73 76 Customer relationships 151 112 39 Third-party technology and licenses 27 14 13 Total amortizable intangible assets 1,182 845 337 In-Process R&D 24 — 24 Total $ 1,206 $ 845 $ 361 As of April 30, 2018 Purchased technology $ 858 $ 676 $ 182 Trademark/Tradename 149 80 69 Customer relationships 151 124 27 Third-party technology and licenses 28 17 11 Total amortizable intangible assets 1,186 897 289 In-Process R&D 25 — 25 Total $ 1,211 $ 897 $ 314
Schedule of estimated future amortization expense of finite-lived intangible assets	Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2018 and for each of the five succeeding fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) Remainder of 2018 $ 47 2019 $ 71 2020 $ 56 2021 $ 42 2022 $ 31 2023 $ 21 Thereafter $ 21

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Apr. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Assets And Liabilities Measured On Recurring Basis	Financial assets and liabilities measured at fair value on a recurring basis as of April 30, 2018 were as follows: Fair Value Measurement at April 30, 2018 Using April 30, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 2,171 $ 2,171 $ — $ — Derivative instruments (foreign exchange contracts) 6 — 6 — Long-term Trading securities 30 30 — — Total assets measured at fair value $ 2,207 $ 2,201 $ 6 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 8 $ — $ 8 $ — Long-term Deferred compensation liability 30 — 30 — Total liabilities measured at fair value $ 38 $ — $ 38 $ — Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2017 were as follows: Fair Value Measurement at October 31, 2017 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,659 $ 1,659 $ — $ — Derivative instruments (foreign exchange contracts) 4 — 4 — Long-term Trading securities 32 32 — — Total assets measured at fair value $ 1,695 $ 1,691 $ 4 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 6 $ — $ 6 $ — Long-term Deferred compensation liability 32 — 32 — Total liabilities measured at fair value $ 38 $ — $ 38 $ —

DERIVATIVES (Tables)

DERIVATIVES (Tables)	6 Months Ended
	Apr. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Aggregated notional amounts by currency and designation	The aggregated notional amounts by currency and designation as of April 30, 2018 were as follows: Derivatives Designated as Cash Flow Hedges Derivatives Not Designated as Hedging Instruments Forward Contracts USD Forward Contracts USD Currency Buy/(Sell) Buy/(Sell) (in millions) Euro $ (67 ) $ 77 British Pound (48 ) (3 ) Canadian Dollar (41 ) 3 Australian Dollar 5 15 Malaysian Ringgit — (1 ) Japanese Yen (64 ) 9 Danish Krone — 26 Korean Won (42 ) — Singapore Dollar 15 — Swiss Franc — 36 Chinese Yuan Renminbi (45 ) — Polish Zloty — (8 ) Swedish Krona — (10 ) Other — (7 ) Totals $ (287 ) $ 137
Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet	Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of April 30, 2018 and October 31, 2017 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location April 30, October 31, Balance Sheet Location April 30, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 3 $ 2 Other accrued liabilities $ 3 $ 2 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 3 $ 2 Other accrued liabilities $ 5 $ 4 Total derivatives $ 6 $ 4 $ 8 $ 6
Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations	The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows: Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 (in millions) Derivatives designated as hedging instruments: Cash Flow Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive income (loss) $ 5 $ (1 ) $ (5 ) $ 1 Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales $ (5 ) $ 1 $ (5 ) $ 2 Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense) $ (5 ) $ — $ 1 $ (3 )

RETIREMENT PLANS AND POST RET31

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)	6 Months Ended
	Apr. 30, 2018
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Schedule of net pension and post-retirement benefit costs	Components of net periodic costs. For the three and six months ended April 30, 2018 and 2017 , our net pension and post retirement benefit costs were comprised of the following: Three Months Ended April 30, U.S. Non-U.S. U.S. Post Retirement Benefit Plans 2018 2017 2018 2017 2018 2017 (in millions) Service cost—benefits earned during the period $ — $ — $ 4 $ 4 $ — $ — Interest cost on benefit obligation 4 5 3 3 1 2 Expected return on plan assets (7 ) (6 ) (12 ) (10 ) (2 ) (2 ) Amortization: Actuarial losses — 1 8 9 2 2 Prior service credits — (1 ) — — (2 ) (2 ) Total net plan costs $ (3 ) $ (1 ) $ 3 $ 6 $ (1 ) $ — Settlements gains $ — $ — $ — $ — $ — $ —

WARRANTIES AND CONTINGENCIES (T

WARRANTIES AND CONTINGENCIES (Tables)	6 Months Ended
	Apr. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Standard warranty	A summary of the standard warranty accrual activity is shown in the table below: Six Months Ended April 30, 2018 2017 (in millions) Beginning balance as of November 1, $ 34 $ 35 Accruals for warranties including change in estimate 25 24 Settlements made during the period (26 ) (25 ) Ending balance as of April 30, $ 33 $ 34 Accruals for warranties due within one year $ 33 $ 33 Accruals for warranties due after one year — 1 Ending balance as of April 30, $ 33 $ 34

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	6 Months Ended
	Apr. 30, 2018
Debt Disclosure [Abstract]
Schedule of Senior Notes and Related Interest Rate Swaps	The following table summarizes the company’s long-term senior notes and the related interest rate swaps: April 30, 2018 October 31, 2017 Amortized Principal Swap Total Amortized Principal Swap Total (in millions) 2020 Senior Notes 499 9 508 499 11 510 2022 Senior Notes 399 — 399 398 — 398 2023 Senior Notes 596 — 596 596 — 596 2026 Senior Notes 297 — 297 297 — 297 Total $ 1,791 $ 9 $ 1,800 $ 1,790 $ 11 $ 1,801

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Apr. 30, 2018
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Three Months Ended April 30, 2018 Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of January 31, 2018 $ (77 ) $ 139 $ (322 ) $ (9 ) $ (269 ) Other comprehensive income (loss) before reclassifications (53 ) — — 5 (48 ) Amounts reclassified out of accumulated other comprehensive income (loss) — (2 ) 10 5 13 Tax expense — — (3 ) (3 ) (6 ) Other comprehensive income (loss) (53 ) (2 ) 7 7 (41 ) As of April 30, 2018 $ (130 ) $ 137 $ (315 ) $ (2 ) $ (310 ) Six Months Ended April 30, 2018 As of October 31, 2017 $ (156 ) $ 140 $ (328 ) $ (2 ) $ (346 ) Other comprehensive income (loss) before reclassifications 26 — (1 ) (5 ) 20 Amounts reclassified out of accumulated other comprehensive income (loss) — (4 ) 19 5 20 Tax (expense) benefit — 1 (5 ) — (4 ) Other comprehensive income (loss) 26 (3 ) 13 — 36 As of April 30, 2018 $ (130 ) $ 137 $ (315 ) $ (2 ) $ (310 )
Reclassification out of Accumulated Other Comprehensive Income	Reclassifications out of accumulated other comprehensive income (loss) for the three and six months ended April 30, 2018 and 2017 were as follows (in millions): Details about accumulated other comprehensive income (loss) components Amounts Reclassified from other comprehensive income (loss) Affected line item in statement of operations Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 Unrealized gain (loss) on derivatives $ (5 ) $ 1 $ (5 ) $ 2 Cost of products (5 ) 1 (5 ) 2 Total before income tax 2 — 2 (1 ) (Provision) benefit for income tax (3 ) 1 (3 ) 1 Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (10 ) (12 ) (19 ) (34 ) Prior service benefit 2 3 4 5 (8 ) (9 ) (15 ) (29 ) Total before income tax 3 2 4 8 Benefit for income tax (5 ) (7 ) (11 ) (21 ) Total net of income tax Total reclassifications for the period $ (8 ) $ (6 ) $ (14 ) $ (20 )

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Apr. 30, 2018
Segment Reporting [Abstract]
Segment Profitability and Segment Assets	The profitability of each of the segments is measured after excluding restructuring and asset impairment charges, transformational initiatives, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below: Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 (in millions) Net Revenue: Life Sciences and Applied Markets $ 561 $ 523 $ 1,179 $ 1,063 Diagnostics and Genomics 219 201 404 365 Agilent CrossLab 426 378 834 741 Total net revenue $ 1,206 $ 1,102 $ 2,417 $ 2,169 Segment Income From Operations: Life Sciences and Applied Markets $ 119 $ 110 $ 278 $ 236 Diagnostics and Genomics 44 49 66 72 Agilent CrossLab 98 82 186 156 Total segment income from operations $ 261 $ 241 $ 530 $ 464 The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets. April 30, October 31, (in millions) Segment Assets: Life Sciences and Applied Markets $ 1,758 $ 1,753 Diagnostics and Genomics 2,136 2,119 Agilent CrossLab 1,173 1,138 Total segment assets $ 5,067 $ 5,010
Reconciliation of segment results to total enterprise results	The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes: Three Months Ended Six Months Ended April 30, April 30, 2018 2017 2018 2017 (in millions) Total reportable segments’ income from operations $ 261 $ 241 $ 530 $ 464 Transformational initiatives (5 ) — (9 ) (2 ) Amortization of intangible assets related to business combinations (25 ) (31 ) (50 ) (62 ) Acquisition and integration costs (4 ) (7 ) (7 ) (21 ) Business exit and divestiture costs (8 ) — (8 ) — Pension settlement gain — — 5 32 NASD site costs (2 ) — (4 ) — Special compliance costs (1 ) — (2 ) — Other (1 ) (2 ) (1 ) (4 ) Interest income 10 5 19 9 Interest expense (19 ) (20 ) (39 ) (40 ) Other income (expense), net 21 5 26 8 Income before taxes, as reported $ 227 $ 191 $ 460 $ 384

OVERVIEW, BASIS OF PRESENTATI36

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions	May 31, 2018	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2017	Oct. 31, 2017
Variable Interest Entity Disclosures
Ownership percentage in Lasergen VIE		48.00%
Call option amount to acquire remaining shares of business		$ 105
Carrying value of investments in VIE's		80
Maximum exposure of investments in VIE's		80
Fair Value of Financial Instruments
Fair value of senior notes in excess of carrying value					$ 58
Fair value of senior notes lower than carrying value		$ 4
Services and other revenue [Member]
Revisions [Abstract]
Prior period revision amount from products to service adjustment			$ 3	$ 6
Services and other cost of sales [Member]
Revisions [Abstract]
Prior period revision amount from products to service adjustment			$ 2	$ 4
Subsequent Event [Member] | Advanced Analytical Technologies, Inc (AATI) [Member]
Acquisition
Purchase Price	$ 250

SHARE-BASED COMPENSATION Alloca

SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017	Oct. 31, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 12	$ 15	$ 43	$ 36
Inventory
Share-based Compensation, Allocation and Classification in Financial Statements
Capitalized share-based compensation			0		$ 0
Cost of Products and Services
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	3	3	10	9
Research and Development Expense
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	1	1	4	3
Selling, General and Administrative Expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 8	$ 11	$ 29	$ 24

SHARE-BASED COMPENSATION Fair V

SHARE-BASED COMPENSATION Fair Value Assumptions (Details)	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award
ESPP plan purchase price (in hundredths)	85.00%	85.00%	85.00%	85.00%
LTPP
Share-based Compensation Arrangement by Share-based Payment Award
Volatility of Agilent shares	21.00%	23.00%	21.00%	23.00%
Volatility of selected peer-company shares - Minimum	14.00%	15.00%	14.00%	15.00%
Volatility of selected peer-company shares - Maximum	66.00%	63.00%	66.00%	63.00%
Price-wise correlation with selected peers (in hundredths)	32.00%	36.00%	32.00%	36.00%
LTPP & RSU
Share-based Compensation Arrangement by Share-based Payment Award
Discount for postvesting restrictions	4.80%	5.30%	4.80%	5.30%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended		12 Months Ended
	Apr. 30, 2018	Jan. 31, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017	Oct. 31, 2018
Income Tax Disclosure
Provision for income taxes	$ 22		$ 27	$ 575	$ 52
Effective income tax rate	9.70%		14.10%	125.00%	13.50%
Net Discrete Tax Expense (Benefit)			$ (1)		$ (3)
U.S. Tax Cuts and Jobs Act of 2017
Income Tax Disclosure
Discrete tax expense (benefit)		$ 533
Net transition tax		480
Estimated provision associated with the impact of decreased U.S. corporate tax rate		53
Provisional income tax expense related to one-time transition tax		643
Income tax benefit due to reversal of deferred tax liability		$ (163)
Share-based compensation [Member]
Income Tax Disclosure
Discrete tax expense (benefit)	$ (7)			$ (18)
Pension Settlement Gain
Income Tax Disclosure
Discrete tax expense (benefit)			11
Settlement with Taxing Authority-Italy
Income Tax Disclosure
Discrete tax expense (benefit)			(7)
Return To Provision Adjustment [Member]
Income Tax Disclosure
Discrete tax expense (benefit)			$ 5		$ 5
Forecast
Income Tax Disclosure
Effective income tax rate						23.00%

NET INCOME PER SHARE (Details)

NET INCOME PER SHARE (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Numerator:
Net income (loss)	$ 205	$ 164	$ (115)	$ 332
Denominators:
Basic weighted-average shares (in shares)	322,000,000	321,000,000	323,000,000	322,000,000
Potential common shares - stock options and other employee stock plans (in shares)	4,000,000	4,000,000	0	3,000,000
Diluted weighted average shares (in shares)	326,000,000	325,000,000	323,000,000	325,000,000
Antidilutive securities excluded from computation of Earnings Per Share, amount (in shares)	96,800	1,000	6,600,000	500

INVENTORY (Details)

INVENTORY (Details) - USD ($) $ in Millions	Apr. 30, 2018	Oct. 31, 2017
Inventory, Net [Abstract]
Finished goods	$ 367	$ 363
Purchased parts and fabricated assemblies	227	212
Inventory	$ 594	$ 575

GOODWILL AND OTHER INTANGIBLE42

GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Roll forward (Details) $ in Millions	6 Months Ended
	Apr. 30, 2018USD ($)
Goodwill Roll Forward
Goodwill beginning balance	$ 2,607
Foreign currency translation impact	6
Goodwill arising from acquisitions	5
Goodwill ending balance	2,618
Life Sciences and Applied Markets
Goodwill Roll Forward
Goodwill beginning balance	818
Foreign currency translation impact	1
Goodwill arising from acquisitions	5
Goodwill ending balance	824
Diagnostics and Genomics
Goodwill Roll Forward
Goodwill beginning balance	1,285
Foreign currency translation impact	5
Goodwill arising from acquisitions	0
Goodwill ending balance	1,290
Agilent CrossLab
Goodwill Roll Forward
Goodwill beginning balance	504
Foreign currency translation impact	0
Goodwill arising from acquisitions	0
Goodwill ending balance	$ 504

GOODWILL AND OTHER INTANGIBLE43

GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Purchased Other Intangibles (Details) - USD ($) $ in Millions	Apr. 30, 2018	Oct. 31, 2017
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	$ 1,211	$ 1,206
Accumulated Amortization	897	845
Net Book Value	314	361
Purchased Technology
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	858	855
Accumulated Amortization	676	646
Net Book Value	182	209
Trademark/Tradenames
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	149	149
Accumulated Amortization	80	73
Net Book Value	69	76
Customer Relationships
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	151	151
Accumulated Amortization	124	112
Net Book Value	27	39
Third-Party Technology and Licenses
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	28	27
Accumulated Amortization	17	14
Net Book Value	11	13
Total amortizable intangible assets
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	1,186	1,182
Accumulated Amortization	897	845
Net Book Value	289	337
In-Process R&D
Indefinite-Lived Intangible Assets (Excluding Goodwill)
In-Process R&D	$ 25	$ 24

GOODWILL AND OTHER INTANGIBLE44

GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Finite-Lived Intangible Assets
Additions to goodwill			$ 5
Addition to other intangible assets			2
Foreign exchange translation impact to other intangible assets			2
Impairment of IPR&D	$ 0	$ 0	0	$ 0
Goodwill impairment	0	0	0	0
Amortization of intangible assets during the period	$ 26	$ 32	52	$ 64
Third-Party Technology and Licenses
Finite-Lived Intangible Assets
Addition to other intangible assets			$ 1

GOODWILL AND OTHER INTANGIBLE45

GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS - Estimated Future Amortization (Details) $ in Millions	Apr. 30, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2018	$ 47
2,019	71
2,020	56
2,021	42
2,022	31
2,023	21
Thereafter	$ 21

FAIR VALUE MEASUREMENTS, Fair v

FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Apr. 30, 2018	Oct. 31, 2017
Assets Short - term
Cash equivalents (money market funds)	$ 2,171	$ 1,659
Derivative instruments (foreign exchange contracts)	6	4
Assets, Long-term
Trading securities	30	32
Total assets measured at fair value	2,207	1,695
Liabilities, Short-term
Derivative instruments (foreign exchange contracts)	8	6
Liabilities Long-term
Deferred compensation liability	30	32
Total liabilities measured at fair value	38	38
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets Short - term
Cash equivalents (money market funds)	2,171	1,659
Derivative instruments (foreign exchange contracts)	0	0
Assets, Long-term
Trading securities	30	32
Total assets measured at fair value	2,201	1,691
Liabilities, Short-term
Derivative instruments (foreign exchange contracts)	0	0
Liabilities Long-term
Deferred compensation liability	0	0
Total liabilities measured at fair value	0	0
Significant Other Observable Inputs (Level 2)
Assets Short - term
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	6	4
Assets, Long-term
Trading securities	0	0
Total assets measured at fair value	6	4
Liabilities, Short-term
Derivative instruments (foreign exchange contracts)	8	6
Liabilities Long-term
Deferred compensation liability	30	32
Total liabilities measured at fair value	38	38
Significant Unobservable Inputs (Level 3)
Assets Short - term
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	0	0
Assets, Long-term
Trading securities	0	0
Total assets measured at fair value	0	0
Liabilities, Short-term
Derivative instruments (foreign exchange contracts)	0	0
Liabilities Long-term
Deferred compensation liability	0	0
Total liabilities measured at fair value	$ 0	$ 0

FAIR VALUE MEASUREMENTS, Fair47

FAIR VALUE MEASUREMENTS, Fair value measures and impairments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Long-Lived Assets
Impairment of Long-Lived Assets Held-for-use	$ 0	$ 0	$ 0	$ 0
Impairment of long-lived assets held for sale	0	0	0	0
Investments
Impairment of Investments	$ 0	$ 0	$ 0	$ 0

DERIVATIVES- Terminated Interes

DERIVATIVES- Terminated Interest Rate Swaps (Details) $ in Millions	Sep. 15, 2016USD ($)	Apr. 30, 2018USD ($)	Oct. 31, 2017USD ($)	Feb. 01, 2016USD ($)contracts	Jul. 01, 2012USD ($)	Aug. 09, 2011USD ($)contracts
Derivative Instruments and Hedging Activities Disclosure
Aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position		$ 5
Terminated Derivative Contracts
Remaining deferred gain (loss) to be amortized on derivative		9	$ 11
Senior Notes 2020
Terminated Derivative Contracts
Remaining deferred gain (loss) to be amortized on derivative		9	11
Senior Notes 2020 | Interest Rate Swap [Member] | Derivatives Designated as Hedging Instrument | Fair Value Hedging
Terminated Derivative Contracts
Number of interest rate swap contracts terminated | contracts						5
Notional amount of contract						$ 500
Remaining deferred gain (loss) to be amortized on derivative		9
Senior Notes 2022
Terminated Derivative Contracts
Remaining deferred gain (loss) to be amortized on derivative		0	0
Senior Notes 2022 | Treasury Lock [Member] | Derivatives Designated as Hedging Instrument | Cash Flow Hedging
Terminated Derivative Contracts
Notional amount of contract					$ 400
Remaining gain (loss) to be amortized on derivative		1
Senior Notes 2026
Terminated Derivative Contracts
Remaining deferred gain (loss) to be amortized on derivative		0	$ 0
Senior Notes 2026 | Interest Rate Swap [Member] | Derivatives Designated as Hedging Instrument | Cash Flow Hedging
Terminated Derivative Contracts
Number of interest rate swap contracts terminated | contracts				3
Notional amount of contract				$ 300
Interest rate swap payments	$ 10
Remaining gain (loss) to be amortized on derivative		$ 8

DERIVATIVES- Foreign Exchange F

DERIVATIVES- Foreign Exchange Forward Contracts(Details) $ in Millions	Apr. 30, 2018USD ($)contracts
Foreign Exchange Forward | Derivatives Designated as Hedging Instrument | Cash Flow Hedging
Derivative
Number of foreign exchange forward contracts (in units) | contracts	110
Foreign Exchange Forward | Derivatives Not Designated as Hedging Instruments
Derivative
Number of foreign exchange forward contracts (in units) | contracts	156
Sell | Forward Contracts USD | Cash Flow Hedging
Derivative
Total notional amount	$ 287
Sell | Forward Contracts USD | Cash Flow Hedging | Euro
Derivative
Total notional amount	67
Sell | Forward Contracts USD | Cash Flow Hedging | British Pound
Derivative
Total notional amount	48
Sell | Forward Contracts USD | Cash Flow Hedging | Canadian Dollar
Derivative
Total notional amount	41
Sell | Forward Contracts USD | Cash Flow Hedging | Japanese Yen
Derivative
Total notional amount	64
Sell | Forward Contracts USD | Cash Flow Hedging | Korean Won
Derivative
Total notional amount	42
Sell | Forward Contracts USD | Cash Flow Hedging | Chinese Yuan Renminbi
Derivative
Total notional amount	45
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | British Pound
Derivative
Total notional amount	3
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Malaysian Ringgit
Derivative
Total notional amount	1
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Polish Zloty
Derivative
Total notional amount	8
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Swedish Krona
Derivative
Total notional amount	10
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Other
Derivative
Total notional amount	7
Buy | Forward Contracts USD | Cash Flow Hedging | Australian Dollar
Derivative
Total notional amount	5
Buy | Forward Contracts USD | Cash Flow Hedging | Singapore Dollar
Derivative
Total notional amount	15
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	137
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Euro
Derivative
Total notional amount	77
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Canadian Dollar
Derivative
Total notional amount	3
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Australian Dollar
Derivative
Total notional amount	15
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Japanese Yen
Derivative
Total notional amount	9
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Danish Krone
Derivative
Total notional amount	26
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Swiss Franc
Derivative
Total notional amount	$ 36

DERIVATIVES, Fair value of deri

DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) - USD ($) $ in Millions	Apr. 30, 2018	Oct. 31, 2017
Derivative Fair Value by Balance Sheet Location
Total derivatives Asset	$ 6	$ 4
Total derivatives Liabilities	8	6
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts [Member] | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Total derivatives Asset	3	2
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts [Member] | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Total derivatives Liabilities	3	2
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts [Member] | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Total derivatives Asset	3	2
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts [Member] | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Total derivatives Liabilities	$ 5	$ 4

DERIVATIVES, Effect of derivati

DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Derivative
Gain (loss) recognized in accumulated other comprehensive income (loss)	$ 5		$ (5)
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales	(5)	$ 1	(5)	$ 2
Cash Flow Hedging | Cost of Sales
Derivative
Cash flow hedge net loss to be reclassified within next Twelve Months	2
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts [Member] | Accumulated Other Comprehensive Income (Loss)
Derivative
Gain (loss) recognized in accumulated other comprehensive income (loss)	5	(1)	(5)	1
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts [Member] | Cost of Sales
Derivative
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales	(5)	1	(5)	2
Derivatives Not Designated as Hedging Instruments | Other income (expense)
Derivative
Gain (loss) recognized in other income (expense)	$ (5)	$ 0	$ 1	$ (3)

RETIREMENT PLANS AND POST RET52

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS- Components of net periodic costs (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Curtailments and Settlements
Settlement gain (loss)	$ 0	$ 0	$ 5	$ 32
Pensions (U.S. Plans)
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	0	0	0	0
Interest cost on benefit obligation	4	5	8	8
Expected return on plan assets	(7)	(6)	(14)	(12)
Amortization:
Actuarial losses	0	1	0	2
Prior service credits	0	(1)	0	(1)
Total net plan costs	(3)	(1)	(6)	(3)
Pensions (Non-U.S. Plans)
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	4	4	10	8
Interest cost on benefit obligation	3	3	6	6
Expected return on plan assets	(12)	(10)	(23)	(20)
Amortization:
Actuarial losses	8	9	15	18
Prior service credits	0	0	0	0
Total net plan costs	3	6	8	12
Curtailments and Settlements
Settlement gain (loss)	0	0	5.2	32
United States Post-retirement Benefit Plan
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	0	0	0	0
Interest cost on benefit obligation	1	2	2	3
Expected return on plan assets	(2)	(2)	(4)	(4)
Amortization:
Actuarial losses	2	2	4	5
Prior service credits	(2)	(2)	(4)	(4)
Total net plan costs	$ (1)	$ 0	$ (2)	$ 0

RETIREMENT PLANS AND POST RET53

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (Textual) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Pensions (U.S. Plans)
Defined Benefit Plans Contributions
Contributions to defined benefit plans	$ 0	$ 25	$ 0	$ 25
Estimated future employer contributions in remainder of current fiscal year	0
Pensions (Non-U.S. Plans)
Defined Benefit Plans Contributions
Contributions to defined benefit plans	5	$ 6	$ 11	$ 9
Estimated future employer contributions in remainder of current fiscal year	$ 12

RETIREMENT PLANS AND POST RET54

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS - JWPIL (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Defined Benefit Plan Disclosure
Settlement gain (loss)	$ 0	$ 0	$ 5	$ 32
Pensions (Non-U.S. Plans)
Defined Benefit Plan Disclosure
Settlement gain (loss)	$ 0	0	$ 5.2	32
Benefit Obligation		65		65
Fair Value of Plan Assets Transferred		$ 24		24
Pensions (Non-U.S. Plans) | Difference Between Fair Values of the Obligation Settled and Assets Transferred
Defined Benefit Plan Disclosure
Settlement gain (loss)				41
Accumulated Other Comprehensive Income | Pensions (Non-U.S. Plans)
Defined Benefit Plan Disclosure
Settlement gain (loss)				$ (9)

WARRANTIES AND CONTINGENCIES (D

WARRANTIES AND CONTINGENCIES (Details) - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017
Movement in Standard Product Warranty Accrual
Beginning balance at beginning of period	$ 34	$ 35
Accruals for warranties including change in estimate	25	24
Settlements made during the period	(26)	(25)
Ending balance at end of period	33	34
Standard Product Warranty Disclosure
Accruals for warranties due within one year	33	33
Accruals for warranties due after one year	0	1
Ending balance at end of period	$ 33	$ 34

SHORT-TERM DEBT Credit Facility

SHORT-TERM DEBT Credit Facility (Details) - USD ($) $ in Millions	Sep. 15, 2014	Apr. 30, 2018	Jul. 14, 2017	Jun. 09, 2015
Line of Credit Facility
Initiation date of credit facility	Sep. 15, 2014
Expiration date of credit facility	Sep. 15, 2019
Initial maximum borrowing capacity of credit facility	$ 400
Credit faciity terms (in years)	five
Credit facility limit increase			$ 300	$ 300
New maximum borrowing capacity of credit facility		$ 1,000
Amount outstanding on credit facility		$ 315

SHORT-TERM DEBT Senior Notes (D

SHORT-TERM DEBT Senior Notes (Details) - Senior Notes 2017 - USD ($) $ in Millions	Oct. 20, 2014	Oct. 24, 2007	Nov. 01, 2017
Short-term Debt
Debt issuance date		Oct. 24, 2007
Aggregate face amount		$ 600
Amount of extinguishment of debt	$ 500
Payment of 2017 Senior Notes			$ 100

LONG-TERM DEBT (Details)

LONG-TERM DEBT (Details) - USD ($) $ in Millions	Apr. 30, 2018	Oct. 31, 2017
Debt Instrument
Long-term debt	$ 1,791	$ 1,790
Interest rate swap	9	11
Long-term Debt, Excluding Current Maturities	1,800	1,801
Senior Notes 2020
Debt Instrument
Long-term debt	499	499
Interest rate swap	9	11
Long-term Debt, Excluding Current Maturities	508	510
Senior Notes 2022
Debt Instrument
Long-term debt	399	398
Interest rate swap	0	0
Long-term Debt, Excluding Current Maturities	399	398
Senior Notes 2023
Debt Instrument
Long-term debt	596	596
Interest rate swap	0	0
Long-term Debt, Excluding Current Maturities	596	596
Senior Notes 2026
Debt Instrument
Long-term debt	297	297
Interest rate swap	0	0
Long-term Debt, Excluding Current Maturities	$ 297	$ 297

STOCKHOLDERS' EQUITY - Stock Re

STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017	May 28, 2015
Share repurchase program
Aggregate cost of shares repurchased			$ 93	$ 194
Treasury Stock Retired
Number of treasury shares retired (is shares)	711,000	1,600,000	1,300,000	4,100,000
Aggregate cost of treasury shares retired	$ 49	$ 83	$ 93	$ 194
2015 Repurchase Program
Share repurchase program
Share repurchase program authorized amount					$ 1,140
Shares repurchased (in shares)	674,000	1,600,000	1,300,000	4,100,000
Aggregate cost of shares repurchased	$ 46	$ 83	$ 93	$ 194
Remaining authorized repurchase amount under share repurchase program	$ 517		$ 517

STOCKHOLDER"S EQUITY - Dividend

STOCKHOLDER"S EQUITY - Dividends (Details) - USD ($) $ / shares in Units, $ in Millions	May 16, 2018	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Dividends Paid
Cash dividends paid per common share		$ 0.149	$ 0.132	$ 0.298	$ 0.264
Aggregate amount of cash dividends paid		$ 48	$ 43	$ 96	$ 85
Subsequent Event [Member]
Dividends Declared
Dividends - Date Declared	May 16, 2018
Dividends declared per share	$ 0.149
Aggregate dividends declared	$ 48
Date dividends to be paid	Jul. 25, 2018
Date of Record	Jul. 3, 2018

STOCKHOLDER'S EQUITY - Accumula

STOCKHOLDER'S EQUITY - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Beginning Balance	$ (269)		$ (346)
Other comprehensive income (loss), before reclassifications	(48)		20
Amounts reclassified out of accumulated other comprehensive income (loss)	13		20
Tax (expense) benefit	(6)		(4)
Other comprehensive income (loss)	(41)	$ 12	36	$ 26
Ending Balance	(310)		(310)
Foreign currency translation
Beginning balance	(77)		(156)
Other comprehensive income (loss) before reclassifications	(53)		26
Amounts reclassified out of accumulated other comprehensive income (loss)	0		0
Tax (expense) benefit	0	(1)	0	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(53)	7	26	4
Ending balance	(130)		(130)
Prior service credits
Beginning balance	139		140
Other comprehensive income (loss) before reclassifications	0		0
Amounts reclassified out of accumulated other comprehensive income (loss)	(2)	(3)	(4)	(5)
Tax (expense) benefit	0		1
Other comprehensive income (loss)	(2)	(2)	(3)	(3)
Ending balance	137		137
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), before Tax
Beginning balance	(322)		(328)
Other comprehensive income (loss) before reclassifications	0		(1)
Amounts reclassified out of accumulated other comprehensive income (loss)	10	12	19	34
Tax (expense) benefit	(3)		(5)
Other comprehensive income (loss)	7	$ 9	13	$ 26
Ending balance	(315)		(315)
Unrealized gains (losses) on derivatives
Beginning balance	(9)		(2)
Other comprehensive income (loss) before reclassifications	5		(5)
Amounts reclassified out of accumulated other comprehensive income (loss)	5		5
Tax (expense) benefit	(3)		0
Other comprehensive income (loss)	7		0
Ending balance	$ (2)		$ (2)

STOCKHOLDERS' EQUITY - Reclassi

STOCKHOLDERS' EQUITY - Reclassifications out of accumulated comprehensive income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives
Unrealized gain (loss) on derivatives	$ (5)	$ 1	$ (5)	$ 2
Unrealized gains and (losses) on derivatives reclassified to cost of products, before tax	(5)	1	(5)	2
Reclassification of (gains) and losses into earnings related to derivative instruments, tax	2	0	2	(1)
Unrealized gains and (losses) on derivatives reclassified to cost of products, net of tax	(3)	1	(3)	1
Actuarial net loss	(10)	(12)	(19)	(34)
Prior service benefit	2	3	4	5
Actuarial net loss and prior service benefit reclassified, before tax	(8)	(9)	(15)	(29)
Tax on actuarial net loss and prior service benefit reclassified	3	2	4	8
Actuarial net loss and prior service benefit reclassified, net of tax	(5)	(7)	(11)	(21)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	$ (8)	$ (6)	$ (14)	$ (20)

SEGMENT INFORMATION - Profitabi

SEGMENT INFORMATION - Profitability (Details) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018USD ($)	Apr. 30, 2017USD ($)	Apr. 30, 2018USD ($)	Apr. 30, 2017USD ($)
Segment Reporting Information
Number of operating segments	3
Segment Reporting Information
Net revenue	$ 1,206	$ 1,102	$ 2,417	$ 2,169
Income from operations	215	201	454	407
Life Sciences and Applied Markets
Segment Reporting Information
Net revenue	561	523	1,179	1,063
Income from operations	119	110	278	236
Diagnostics and Genomics
Segment Reporting Information
Net revenue	219	201	404	365
Income from operations	44	49	66	72
Agilent CrossLab
Segment Reporting Information
Net revenue	426	378	834	741
Income from operations	98	82	186	156
Segment Total
Segment Reporting Information
Net revenue	1,206	1,102	2,417	2,169
Income from operations	$ 261	$ 241	$ 530	$ 464

SEGMENT INFORMATION - Reconcili

SEGMENT INFORMATION - Reconciliation of Reportable Results (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
Total reportable segment's income from operations	$ 261	$ 241	$ 530	$ 464
Transformational initiatives	(5)	0	(9)	(2)
Amortization of intangible assets related to business combinations	(25)	(31)	(50)	(62)
Acquisition and integration costs	(4)	(7)	(7)	(21)
Business exit and divestiture costs	(8)	0	(8)	0
Pension settlement gain	0	0	5	32
NASD site costs	(2)	0	(4)	0
Special compliance costs	(1)	0	(2)	0
Other	(1)	(2)	(1)	(4)
Interest income	10	5	19	9
Interest expense	(19)	(20)	(39)	(40)
Other income (expense), net	21	5	26	8
Income before taxes, as reported	$ 227	$ 191	$ 460	$ 384

SEGMENT INFORMATION - Segment A

SEGMENT INFORMATION - Segment Assets (Details) - USD ($) $ in Millions	Apr. 30, 2018	Oct. 31, 2017
Segment Reporting Information
Assets	$ 8,784	$ 8,426
Life Sciences and Applied Markets
Segment Reporting Information
Assets	1,758	1,753
Diagnostics and Genomics
Segment Reporting Information
Assets	2,136	2,119
Agilent CrossLab
Segment Reporting Information
Assets	1,173	1,138
Segment Total
Segment Reporting Information
Assets	$ 5,067	$ 5,010

SUBSEQUENT EVENTS - (Details)

SUBSEQUENT EVENTS - (Details) - Subsequent Event [Member] - USD ($) $ / shares in Units, $ in Millions	May 31, 2018	May 25, 2018	May 16, 2018	May 14, 2018	May 07, 2018
Dividends Declared
Dividends - Date Declared			May 16, 2018
Dividends declared per share			$ 0.149
Aggregate dividends declared			$ 48
Date dividends to be paid			Jul. 25, 2018
Date of Record			Jul. 3, 2018
Lasergen
Acquisitions
Purchase Price					$ 105
Genohm SA
Acquisitions
Purchase Price				$ 40
Ultra Scientific Inc. & Young In Scientific Co. Ltd
Acquisitions
Cash consideration to be paid upon close		$ 60
Advanced Analytical Technologies, Inc
Acquisitions
Purchase Price	$ 250